Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Highlights of Asian Cup 2022China's first selfKylian Mbappe informs PSG he will not trigger contract extensionSki resorts in east China make full preparations during Spring Festival holidayXi Story: A Champion of Closer PeopleXi Pledges China's Continuous Support for Cuba in Opposing InterferenceChinese paddlers Wang, Sun lift trophies at WTT Cup FinalsBeijing 2022 Olympic athletes honored at ANOC Awards 2022China Focus: China embraces wider winter sports, leisure participationNetherlands, Senegal, England, U.S. advance
2.6504s , 6500.8125 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Cosmic Chronicle news portal